Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VIMSELTINIB vs VISMODEGIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

VIMSELTINIB vs VISMODEGIB: Safety Overview

Metric VIMSELTINIB VISMODEGIB
Total FAERS Reports 170 8,135
Deaths Reported 0 864
Death Rate N/A 10.6%
Hospitalizations 5 974
Average Patient Age 45.6 yrs 69.6 yrs
% Female Patients 55.4% 39.3%
FDA Approval Date Feb 14, 2025 Jan 30, 2012
Manufacturer Deciphera Pharmaceuticals, LLC Genentech, Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription